More on URGN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $32.81 |
|
|||
| Open | $33.45 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $33.79 | ||||
| Day Low | $32.21 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 847,100 | ||||
- Form 4 UroGen Pharma Ltd. For: Jun 08 Filed by: Schoenberg Mark
- Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
- Oppenheimer on UroGen Pharma (URGN): 'We expect Zusduri's continued launch to drive outperformance'
- Form 8-K UroGen Pharma Ltd. For: Jun 02
- UroGen settles JELMYTO patent litigation with Teva
- UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
- UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Form ARS UroGen Pharma Ltd. For: Dec 31
Entities mentioned with URGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
